Rungtip Darayon, Tarika Kanphet, P. Dandecha, S. Jamulitrat
Objective: To analyze the results from the surveillance of hemodialysis-related infections.Material and Methods: Data was prospectively gathered from outpatients attending a hemodialysis unit from April 2019 until March 2023. The National Healthcare Safety Network (NHSN) Dialysis Event Surveillance was used to identify three types of infection-related dialysis events. Event rates were calculated and stratified by vascular access type, standardized infection ratios for bloodstream infections (BSI), intravenous antimicrobial starts, and described pathogens identified among BSI.Results: A total of 2,288 patient-month follow-ups were included. There were 79 infection-related dialysis events (24 BSI; 46 intravenous antimicrobial starts, nine pus, redness, or increased swelling at the vascular access site). The incidence of BSI per 100 patient-months was 1.05 (0.59 arteriovenous fistula, 0.83 arteriovenous graft, and 2.22 central venous catheter). Seventeen BSI were vascular access-related. Access-related BSI per 100 patient-months was 0.74 (0.39 arteriovenous fistula, 0.41 arteriovenous graft, and 1.85 central venous catheter). Intravenous antimicrobial starts per 100 patient-months was 2.01 (0.98 arteriovenous fistula, 2.62 arteriovenous graft, and 3.14 central venous catheter). Most events occurred in patients with a central venous catheter. When benchmarked with the 2014 NHSN, the standardized infection ratio of BSI, access-related BSI, and intravenous antimicrobial starts were 1.40, 1.26, and 0.55, respectively. The most serious outcome was BSI; resulting in 83.3% hospitalizations, 25% loss of vascular access, and 15.8% deaths. Conclusion: Surveillance of infection-related dialysis events is important for prevention. These events were highest among patients with a central venous catheter compared with other vascular access types.
{"title":"Hemodialysis-Related Infections: A 4-Year Surveillance","authors":"Rungtip Darayon, Tarika Kanphet, P. Dandecha, S. Jamulitrat","doi":"10.31584/jhsmr.20241043","DOIUrl":"https://doi.org/10.31584/jhsmr.20241043","url":null,"abstract":"Objective: To analyze the results from the surveillance of hemodialysis-related infections.Material and Methods: Data was prospectively gathered from outpatients attending a hemodialysis unit from April 2019 until March 2023. The National Healthcare Safety Network (NHSN) Dialysis Event Surveillance was used to identify three types of infection-related dialysis events. Event rates were calculated and stratified by vascular access type, standardized infection ratios for bloodstream infections (BSI), intravenous antimicrobial starts, and described pathogens identified among BSI.Results: A total of 2,288 patient-month follow-ups were included. There were 79 infection-related dialysis events (24 BSI; 46 intravenous antimicrobial starts, nine pus, redness, or increased swelling at the vascular access site). The incidence of BSI per 100 patient-months was 1.05 (0.59 arteriovenous fistula, 0.83 arteriovenous graft, and 2.22 central venous catheter). Seventeen BSI were vascular access-related. Access-related BSI per 100 patient-months was 0.74 (0.39 arteriovenous fistula, 0.41 arteriovenous graft, and 1.85 central venous catheter). Intravenous antimicrobial starts per 100 patient-months was 2.01 (0.98 arteriovenous fistula, 2.62 arteriovenous graft, and 3.14 central venous catheter). Most events occurred in patients with a central venous catheter. When benchmarked with the 2014 NHSN, the standardized infection ratio of BSI, access-related BSI, and intravenous antimicrobial starts were 1.40, 1.26, and 0.55, respectively. The most serious outcome was BSI; resulting in 83.3% hospitalizations, 25% loss of vascular access, and 15.8% deaths. Conclusion: Surveillance of infection-related dialysis events is important for prevention. These events were highest among patients with a central venous catheter compared with other vascular access types.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"6 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140244460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To evaluate the outcomes and safety of the surgical technique Retzius-sparing robot-assisted laparoscopic radical prostatectomy (RS-RALRP), with prostatic cancer; the first report in Thailand. Material and Methods: The authors conducted a retrospective analysis from the medical records of 100 patients who underwent RS-RALRP by a single surgeon; from 1st January 2021 until 31st May 2023, at Rajavithi Hospital. The authors analyzed demographic data, clinical staging, Gleason grade group, operative time, pathologic staging, positive surgical margin rate; postoperative continence recovery and postoperative complications. Results: The median age was 71.34±6.84 years: mean total PSA was 17.16±17.55 ng/ml; with the majority in clinical T1 and T2. The mean operative time was 221.7±51.93 minutes, and the mean estimated blood loss was 312.30±264.55 ml. Of all patients, 88% did not require blood transfusion. The complication rate was 8%. The pathologic stages pT2 and pT3 or greater were 62% and 38%, respectively. Positive surgical margins (PSM) pT2 and pT3 were 14.5% and 63.2%. The postoperative continence recovery after RS-RALRP were 83%, 95%, 97%,100% and 100%: at 1, 3, 6, 9 and 12 months postoperatively, respectively. Conclusion: RS-RALRP has a potential to become the new standard for prostate cancer treatment, with improved early continence and equivalent oncologic efficacy. The limitations of this study are the small number of population, which require prospective multicenter studies.
{"title":"Surgical Experience and Results of Retzius Sparing Robotic Assisted Laparoscopic Radical Prostatectomy: First Report in Thailand","authors":"Tanet Thaidumrong, Sermsin Sindhubodee, Somjith Duangkae","doi":"10.31584/jhsmr.20241040","DOIUrl":"https://doi.org/10.31584/jhsmr.20241040","url":null,"abstract":"Objective: To evaluate the outcomes and safety of the surgical technique Retzius-sparing robot-assisted laparoscopic radical prostatectomy (RS-RALRP), with prostatic cancer; the first report in Thailand. Material and Methods: The authors conducted a retrospective analysis from the medical records of 100 patients who underwent RS-RALRP by a single surgeon; from 1st January 2021 until 31st May 2023, at Rajavithi Hospital. The authors analyzed demographic data, clinical staging, Gleason grade group, operative time, pathologic staging, positive surgical margin rate; postoperative continence recovery and postoperative complications. Results: The median age was 71.34±6.84 years: mean total PSA was 17.16±17.55 ng/ml; with the majority in clinical T1 and T2. The mean operative time was 221.7±51.93 minutes, and the mean estimated blood loss was 312.30±264.55 ml. Of all patients, 88% did not require blood transfusion. The complication rate was 8%. The pathologic stages pT2 and pT3 or greater were 62% and 38%, respectively. Positive surgical margins (PSM) pT2 and pT3 were 14.5% and 63.2%. The postoperative continence recovery after RS-RALRP were 83%, 95%, 97%,100% and 100%: at 1, 3, 6, 9 and 12 months postoperatively, respectively. Conclusion: RS-RALRP has a potential to become the new standard for prostate cancer treatment, with improved early continence and equivalent oncologic efficacy. The limitations of this study are the small number of population, which require prospective multicenter studies.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"21 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140261874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: This study aimed to perform a meta-analysis to ascertain the efficacy and safety of Cannabis in treating ulcerative colitis (UC).Material and Methods: A meta-analysis of randomized controlled trials (RCTs) included in three databases (PubMed, Google Scholar and Science Direct) was performed; from inception till 31st July 2023, so as to ascertain the efficacy and safety of Cannabis in UC. Primary outcomes included: disease activity and endoscopic indices, and quality of life (QOL). The risk of bias in the studies was assessed via the RoB2 tool.Results: In total 1,928 records identified; of which four were eligible for inclusion. The risk of bias in the included studies was moderate. The patients were randomized to the cannabinoid group had significantly improved disease activity indices (standardized mean difference (SMD) -1.78; 95% confidence interval (CI) (-2.89 to 0.67); I2=74%) and QOL (SMD -1.70; 95% CI (0.24 to 3.17); I2=75%) than those in the placebo group. However, cannabinoids did not have a significant impact on endoscopic indices (SMD -0.40; 95% CI (-0.92 to 0.11); I2=0%) nor C-reactive protein (CRP) levels (SMD -0.49; 95% CI (-0.87 to 1.85); I2=85%) of UC patients.Conclusion: Cannabinoids show potential in improving disease activity and QOL; however, their impact on endoscopic indices and CRP levels remains inconclusive.
目的：本研究旨在对大麻治疗溃疡性结肠炎的疗效和安全性进行荟萃分析：本研究旨在进行一项荟萃分析，以确定大麻治疗溃疡性结肠炎（UC）的有效性和安全性：对三个数据库（PubMed、Google Scholar 和 Science Direct）中收录的随机对照试验（RCTs）进行荟萃分析，分析时间从开始至 2023 年 7 月 31 日，以确定大麻治疗溃疡性结肠炎的疗效和安全性。主要结果包括：疾病活动和内窥镜指数以及生活质量（QOL）。研究的偏倚风险通过 RoB2 工具进行评估：共发现 1,928 条记录，其中 4 条符合纳入条件。纳入研究的偏倚风险为中度。与安慰剂组相比，随机分配到大麻素组的患者疾病活动指数（标准化平均差（SMD）-1.78；95% 置信区间（CI）（-2.89 至 0.67）；I2=74%）和 QOL（SMD-1.70；95% CI（0.24 至 3.17）；I2=75%）均有明显改善。然而，大麻素对UC患者的内窥镜指数（SMD -0.40；95% CI (-0.92 to 0.11)；I2=0%）和C反应蛋白（CRP）水平（SMD -0.49；95% CI (-0.87 to 1.85)；I2=85%）没有显著影响：结论：大麻素在改善疾病活动和生活质量方面显示出潜力；但其对内窥镜指数和CRP水平的影响仍不确定。
{"title":"Therapeutic Effects of Cannabinoids on Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Rajesh Kumar, Shruti Singh, V. Maharshi","doi":"10.31584/jhsmr.20241041","DOIUrl":"https://doi.org/10.31584/jhsmr.20241041","url":null,"abstract":"Objective: This study aimed to perform a meta-analysis to ascertain the efficacy and safety of Cannabis in treating ulcerative colitis (UC).Material and Methods: A meta-analysis of randomized controlled trials (RCTs) included in three databases (PubMed, Google Scholar and Science Direct) was performed; from inception till 31st July 2023, so as to ascertain the efficacy and safety of Cannabis in UC. Primary outcomes included: disease activity and endoscopic indices, and quality of life (QOL). The risk of bias in the studies was assessed via the RoB2 tool.Results: In total 1,928 records identified; of which four were eligible for inclusion. The risk of bias in the included studies was moderate. The patients were randomized to the cannabinoid group had significantly improved disease activity indices (standardized mean difference (SMD) -1.78; 95% confidence interval (CI) (-2.89 to 0.67); I2=74%) and QOL (SMD -1.70; 95% CI (0.24 to 3.17); I2=75%) than those in the placebo group. However, cannabinoids did not have a significant impact on endoscopic indices (SMD -0.40; 95% CI (-0.92 to 0.11); I2=0%) nor C-reactive protein (CRP) levels (SMD -0.49; 95% CI (-0.87 to 1.85); I2=85%) of UC patients.Conclusion: Cannabinoids show potential in improving disease activity and QOL; however, their impact on endoscopic indices and CRP levels remains inconclusive.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"12 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140262376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To describe the incidence of extravasation resulting from the administration of norepinephrine through a peripheral venous catheter in emergency patients.Material and Methods: This prospective observational study was conducted on 150 adult patients in the emergency department at Siriraj Hospital, Thailand. Physicians closely monitored patients who received norepinephrine via a peripheral venous catheter examining the intravenous access sites during the period of treatment and for up to 48 hours after discontinuation of treatment. We collected demographic data, norepinephrine administration details, potential risk factors for extravasation, the incidence of extravasation, and mortality rate.Results: The median age of the patients was 67 years, and 60.7% were male. Most patients (93.3%) received peripheral intravenous norepinephrine for septic shock, administered below the wrist joint (47.3%) through a 22-gauge catheter (82.7%). The median duration of total peripheral intravenous norepinephrine administration was 19.92 hours (interquartile range (IQR) 9.48-38.09). The median maximum dose was 0.07 mcg/kg/min (IQR 0.04-0.10). Extravasation occurred in three patients (2.0%) (95% CI: 0.6 - 6.1), none of which resulted in significant morbidity. The timing from shock diagnosis to peripheral intravenous norepinephrine administration did not statistically differ between survivors and non-survivors at both 7 and 30 days. However, the median time from shock diagnosis to achieve mean arterial pressure (MAP)≥65 mmHg, and time from norepinephrine administration to achieve MAP ≥65 mmHg, was shorter in the survivors compared to the non-survivors.Conclusion: Given that the incidence of extravasation events was low and did not result in significant morbidity, we suggest that peripheral intravenous norepinephrine administration is safe under close observation and for a limited duration.
{"title":"Incidence of Extravasation during Norepinephrine Administration via Peripheral Venous Catheter in Emergency Patients","authors":"Diana Karimee, Montira Buakhong, Ploylarp Lertvipapath, Chok Limsuwat","doi":"10.31584/jhsmr.20241039","DOIUrl":"https://doi.org/10.31584/jhsmr.20241039","url":null,"abstract":"Objective: To describe the incidence of extravasation resulting from the administration of norepinephrine through a peripheral venous catheter in emergency patients.Material and Methods: This prospective observational study was conducted on 150 adult patients in the emergency department at Siriraj Hospital, Thailand. Physicians closely monitored patients who received norepinephrine via a peripheral venous catheter examining the intravenous access sites during the period of treatment and for up to 48 hours after discontinuation of treatment. We collected demographic data, norepinephrine administration details, potential risk factors for extravasation, the incidence of extravasation, and mortality rate.Results: The median age of the patients was 67 years, and 60.7% were male. Most patients (93.3%) received peripheral intravenous norepinephrine for septic shock, administered below the wrist joint (47.3%) through a 22-gauge catheter (82.7%). The median duration of total peripheral intravenous norepinephrine administration was 19.92 hours (interquartile range (IQR) 9.48-38.09). The median maximum dose was 0.07 mcg/kg/min (IQR 0.04-0.10). Extravasation occurred in three patients (2.0%) (95% CI: 0.6 - 6.1), none of which resulted in significant morbidity. The timing from shock diagnosis to peripheral intravenous norepinephrine administration did not statistically differ between survivors and non-survivors at both 7 and 30 days. However, the median time from shock diagnosis to achieve mean arterial pressure (MAP)≥65 mmHg, and time from norepinephrine administration to achieve MAP ≥65 mmHg, was shorter in the survivors compared to the non-survivors.Conclusion: Given that the incidence of extravasation events was low and did not result in significant morbidity, we suggest that peripheral intravenous norepinephrine administration is safe under close observation and for a limited duration.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"38 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140424569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Loc Phuoc Trinh, Quyen Nguyen Tu Le, Duong Bui Thuy Le, Duyen Quang Loc Vo, D. Q. Lam, Tam Thi Minh Nguyen, S. T. Pham, Thang Nguyen
Objective: Drug-related problems (DRPs) can lead to treatment failures and high risks of hospitali-zation. This study aimed to evaluate the effect of pharmacist-led interventions on DRPs in outpa-tient prescribing and to determine the risk factors relative to these DRPs.Material and Methods: A prospective study was conducted that compared before- (April 1 to June 30, 2020) and after- (June 1 to June 15, 2021) interventions on the outpatient prescribing process from a public hospital in Vietnam. The PCNE classification version 9.1 and suitable drug information were used to determine DRPs, which then used Drugs.com to find drug-drug interactions for each prescription. Collaborated with hospital pharmacists via reporting on the pre-intervention results, sending information sheets, and reminding doctors of the DRPs was conducted.Results: 32.8% of prescriptions had at least 1 DRP in 500 pre-intervention prescriptions. In 500 post-intervention prescriptions, the proportion of at least 1 DRP prescription decreased from 32.8% to 31.0% (p-value>0.05). Prescriptions with ≥5 drugs increased the possibility of a DRP appearance (p-value<0.001).Conclusion: This intervention method was not thorough, so it was ineffective in reducing DRPs on outpatient prescriptions. It is necessary to conduct specific interventions on each DRP and more time to discuss with doctors to improve the effectiveness of prescribing.
{"title":"Effectiveness of Pharmacist-led Intervention on Physicians Prescribing for Outpatients in Vietnam: A Before- and After-intervention Study","authors":"Loc Phuoc Trinh, Quyen Nguyen Tu Le, Duong Bui Thuy Le, Duyen Quang Loc Vo, D. Q. Lam, Tam Thi Minh Nguyen, S. T. Pham, Thang Nguyen","doi":"10.31584/jhsmr.20241038","DOIUrl":"https://doi.org/10.31584/jhsmr.20241038","url":null,"abstract":"Objective: Drug-related problems (DRPs) can lead to treatment failures and high risks of hospitali-zation. This study aimed to evaluate the effect of pharmacist-led interventions on DRPs in outpa-tient prescribing and to determine the risk factors relative to these DRPs.Material and Methods: A prospective study was conducted that compared before- (April 1 to June 30, 2020) and after- (June 1 to June 15, 2021) interventions on the outpatient prescribing process from a public hospital in Vietnam. The PCNE classification version 9.1 and suitable drug information were used to determine DRPs, which then used Drugs.com to find drug-drug interactions for each prescription. Collaborated with hospital pharmacists via reporting on the pre-intervention results, sending information sheets, and reminding doctors of the DRPs was conducted.Results: 32.8% of prescriptions had at least 1 DRP in 500 pre-intervention prescriptions. In 500 post-intervention prescriptions, the proportion of at least 1 DRP prescription decreased from 32.8% to 31.0% (p-value>0.05). Prescriptions with ≥5 drugs increased the possibility of a DRP appearance (p-value<0.001).Conclusion: This intervention method was not thorough, so it was ineffective in reducing DRPs on outpatient prescriptions. It is necessary to conduct specific interventions on each DRP and more time to discuss with doctors to improve the effectiveness of prescribing.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"52 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140445059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Staporn Kasemsripitak, Somchit Jaruratanasirikul, T. Saengkaew
We describe a 14-year-old girl who was referred for management of a prolactin-secreting pituitary adenoma as she had persistent milky discharge from her nipples, an elevated prolactin level and pituitary enlargement. Upon reviewing the medical history, it was noted that she had a history of secondary amenorrhea for 1 year, and had undergone an oophorectomy for twisted left ovarian cyst 5 months earlier. The physical examination found that she had a goiter, short stature and was relatively overweight. Based on these findings, it was thought that the patient likely had longstanding overt hypothyroidism. A thyroid function test (TFT) revealed a free thyroxine (FT4) level of 0.2 ng/dL and thyroid stimulating hormone (TSH) >100 mU/L, with high levels of antithyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies, leading to the diagnosis of Hashimoto’s thyroiditis. After 8 months of levothyroxine treatment, the galactorrhea had disappeared, the pituitary enlargement had resolved and her menstruation had resumed normally, along with a 4-kg weight loss and 3-cm height gain. In summary, when evaluating a girl with ovarian cyst(s), especially if accompanied by other clinical findings like goiter, short stature, or menstrual irregularities, the physician should include hypothyroidism in the differential diagnosis. Early diagnosis and treatment of hypothyroidism can have a positive impact on the overall health and well-being of these patients, potentially preventing further complications related to both the thyroid disorder and ovarian cyst(s).
{"title":"Twisted Ovarian Cyst, Galactorrhea and Pituitary Hyperplasia Misdiagnosed as Prolactinoma: An Overlooked Longstanding Overt Hypothyroidism from Hashimoto’s Thyroiditis","authors":"Staporn Kasemsripitak, Somchit Jaruratanasirikul, T. Saengkaew","doi":"10.31584/jhsmr.20241033","DOIUrl":"https://doi.org/10.31584/jhsmr.20241033","url":null,"abstract":"We describe a 14-year-old girl who was referred for management of a prolactin-secreting pituitary adenoma as she had persistent milky discharge from her nipples, an elevated prolactin level and pituitary enlargement. Upon reviewing the medical history, it was noted that she had a history of secondary amenorrhea for 1 year, and had undergone an oophorectomy for twisted left ovarian cyst 5 months earlier. The physical examination found that she had a goiter, short stature and was relatively overweight. Based on these findings, it was thought that the patient likely had longstanding overt hypothyroidism. A thyroid function test (TFT) revealed a free thyroxine (FT4) level of 0.2 ng/dL and thyroid stimulating hormone (TSH) >100 mU/L, with high levels of antithyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies, leading to the diagnosis of Hashimoto’s thyroiditis. After 8 months of levothyroxine treatment, the galactorrhea had disappeared, the pituitary enlargement had resolved and her menstruation had resumed normally, along with a 4-kg weight loss and 3-cm height gain. In summary, when evaluating a girl with ovarian cyst(s), especially if accompanied by other clinical findings like goiter, short stature, or menstrual irregularities, the physician should include hypothyroidism in the differential diagnosis. Early diagnosis and treatment of hypothyroidism can have a positive impact on the overall health and well-being of these patients, potentially preventing further complications related to both the thyroid disorder and ovarian cyst(s).","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"89 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139683501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Sukittiwarapun, C. Churuangsuk, T. Inviya, P. Sripongpun, N. Chamroonkul
Objective: We developed a simple nutritional counseling tool for adults with liver cirrhosis, aiming for doctors, nurses, and patients as the tool’s primary users.Material and Methods: The tool was created in a booklet design and based on the European Society of Parenteral and Enteral Nutrition guideline, which comprises four parts, knowledge about cirrhosis, consequences of malnutrition, nutritional recommendations, and calculation of dry body weight and appropriate daily nutritional requirements. Content validity was assessed by three hepatologists using the item objective congruence (IOC) index wherein a score ≥0.5 indicated valid content. Face validity was evaluated by three doctors, three nurses, one dietitian, and three patients for readability, coherence, understandability, and attractiveness using a rating score of 0-10. A reliability test to calculate dry body weight and carbohydrate and protein intake per meal using an intraclass correlation coefficient (ICC) was conducted to determine the agreement among seven doctors and three nurses (inter-raters) using a total of nine case scenarios.Results: The contents of the booklet were valid (IOC: 1.00 for all 19 items). For face validity, the scores for readability, coherence, attractiveness, and understandability were 7.6, 8.6, 9, and 8.6 out of 10, respectively. The overall comments showed that the new instrument was attractive and convenient. All doctors and nurses correctly calculated the dry body weight, and carbohydrate and protein intake for nine case scenarios, indicating excellent agreement (ICC: 1.0, p-value<0.001).Conclusion: The novel nutritional counseling booklet is valid and shows excellent reliability among healthcare providers in calculating body status and nutritional requirements.
{"title":"Development, Validity, and Reliability of an Easy-to-Use Nutrition Counseling Tool for Thai Outpatients with Liver Cirrhosis","authors":"N. Sukittiwarapun, C. Churuangsuk, T. Inviya, P. Sripongpun, N. Chamroonkul","doi":"10.31584/jhsmr.20241032","DOIUrl":"https://doi.org/10.31584/jhsmr.20241032","url":null,"abstract":"Objective: We developed a simple nutritional counseling tool for adults with liver cirrhosis, aiming for doctors, nurses, and patients as the tool’s primary users.Material and Methods: The tool was created in a booklet design and based on the European Society of Parenteral and Enteral Nutrition guideline, which comprises four parts, knowledge about cirrhosis, consequences of malnutrition, nutritional recommendations, and calculation of dry body weight and appropriate daily nutritional requirements. Content validity was assessed by three hepatologists using the item objective congruence (IOC) index wherein a score ≥0.5 indicated valid content. Face validity was evaluated by three doctors, three nurses, one dietitian, and three patients for readability, coherence, understandability, and attractiveness using a rating score of 0-10. A reliability test to calculate dry body weight and carbohydrate and protein intake per meal using an intraclass correlation coefficient (ICC) was conducted to determine the agreement among seven doctors and three nurses (inter-raters) using a total of nine case scenarios.Results: The contents of the booklet were valid (IOC: 1.00 for all 19 items). For face validity, the scores for readability, coherence, attractiveness, and understandability were 7.6, 8.6, 9, and 8.6 out of 10, respectively. The overall comments showed that the new instrument was attractive and convenient. All doctors and nurses correctly calculated the dry body weight, and carbohydrate and protein intake for nine case scenarios, indicating excellent agreement (ICC: 1.0, p-value<0.001).Conclusion: The novel nutritional counseling booklet is valid and shows excellent reliability among healthcare providers in calculating body status and nutritional requirements.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"47 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139683975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Norhanis Farina Abdul Razak, Ayu Suzailiana Muhamad, Ambra Gentile, Marilyn Li Yin Ong
Objective: This cross-sectional study assessed the prevalence of health complaints and physical activity levels among female university students; including determining the risk factors of health complaints during the pandemic.Material and Methods: Data were collected from 205 female university students, aged 18-29 years old via self-administered online questionnaires during a nationwide movement-restricted order. The Global Physical Activity Questionnaire (GPAQ) and a modified health symptoms questionnaire were used to assess physical activity levels and health complaints.Results: The most prevalent daily health complaint was sleeping difficulties (8.3%). The total minutes of sedentary behaviour were positively associated with health complaints (r=0.131, p-value=0.031), while the total minutes of moderate recreation were negatively associated with health complaints (r=-0.166, p-value=0.009). Marital status (standardised beta coefficient, β=-0.167, p-value=0.030) and employment (β=-0.180, p-value=0.017) were risks of health complaints.Conclusion: Sedentariness; including sociodemographic factors during the pandemic was associated with healthcomplaints. Appropriate counselling, finance and social supports and physical activity programmes are recommended atuniversities to prevent future health risks.
{"title":"Physical Activity Levels and Associated Factors for Health Complaints among Female University Students During the COVID-19 Pandemic in Malaysia: A University-based Cross-Sectional Survey","authors":"Norhanis Farina Abdul Razak, Ayu Suzailiana Muhamad, Ambra Gentile, Marilyn Li Yin Ong","doi":"10.31584/jhsmr.20241031","DOIUrl":"https://doi.org/10.31584/jhsmr.20241031","url":null,"abstract":"Objective: This cross-sectional study assessed the prevalence of health complaints and physical activity levels among female university students; including determining the risk factors of health complaints during the pandemic.Material and Methods: Data were collected from 205 female university students, aged 18-29 years old via self-administered online questionnaires during a nationwide movement-restricted order. The Global Physical Activity Questionnaire (GPAQ) and a modified health symptoms questionnaire were used to assess physical activity levels and health complaints.Results: The most prevalent daily health complaint was sleeping difficulties (8.3%). The total minutes of sedentary behaviour were positively associated with health complaints (r=0.131, p-value=0.031), while the total minutes of moderate recreation were negatively associated with health complaints (r=-0.166, p-value=0.009). Marital status (standardised beta coefficient, β=-0.167, p-value=0.030) and employment (β=-0.180, p-value=0.017) were risks of health complaints.Conclusion: Sedentariness; including sociodemographic factors during the pandemic was associated with healthcomplaints. Appropriate counselling, finance and social supports and physical activity programmes are recommended atuniversities to prevent future health risks.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"41 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140479074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Siwanon Nawalerspanya, Kontee Wongseree, P. Sripongpun, N. Chamroonkul, A. Kaewdech
Autoimmune hepatitis (AIH) is a rare condition that has seldom been reported being reactivated by a coronavirus disease 2019 (COVID-19) vaccination, especially from an inactivated vaccine. This report presents the case of a 64-year-old male with quiescent AIH cirrhosis who exhibited jaundice and constitutional symptoms for three days at two weeks following his second dose of an inactivated vaccine. The patient had complied well with a four-year immunosuppressive medication regimen to treat AIH which maintained normalized liver enzymes. He also abstained from using herbal supplements. At his presentation, his liver chemistry showed acute hepatocellular jaundice, with histology revealing active AIH. Following extensive testing, he was diagnosed with an AIH exacerbation triggered by the COVID-19 vaccine. His symptoms improved following treatment with higher doses of immunosuppressive agents. This report underscores the potential effect of the COVID-19 vaccine on reactivating well-controlled AIH.
{"title":"Exacerbation of Autoimmune Hepatitis following Inactivated SARS-CoV-2 Vaccination","authors":"Siwanon Nawalerspanya, Kontee Wongseree, P. Sripongpun, N. Chamroonkul, A. Kaewdech","doi":"10.31584/jhsmr.20241030","DOIUrl":"https://doi.org/10.31584/jhsmr.20241030","url":null,"abstract":"Autoimmune hepatitis (AIH) is a rare condition that has seldom been reported being reactivated by a coronavirus disease 2019 (COVID-19) vaccination, especially from an inactivated vaccine. This report presents the case of a 64-year-old male with quiescent AIH cirrhosis who exhibited jaundice and constitutional symptoms for three days at two weeks following his second dose of an inactivated vaccine. The patient had complied well with a four-year immunosuppressive medication regimen to treat AIH which maintained normalized liver enzymes. He also abstained from using herbal supplements. At his presentation, his liver chemistry showed acute hepatocellular jaundice, with histology revealing active AIH. Following extensive testing, he was diagnosed with an AIH exacerbation triggered by the COVID-19 vaccine. His symptoms improved following treatment with higher doses of immunosuppressive agents. This report underscores the potential effect of the COVID-19 vaccine on reactivating well-controlled AIH. ","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"38 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140477457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jarawee Sukmanee, Penkae Rothmanee, Wilaiwan Sriwimol, Anne Cathrine, T. Liabsuetrakul
Objective: To measure and compare cardiovascular biomarkers and blood pressure in women with hypertensive disorders of pregnancy (HDP) to those with normotensive pregnancies evaluated at 6 weeks and 6-12 months after delivery.Material and Methods: A prospective cohort study of postpartum women following HDP and normotensive pregnancies at 6 weeks and 6-12 months postpartum was conducted. Postpartum blood pressure and cardiovascular biomarkers including body mass index (BMI), levels of serum high-sensitivity C-reactive protein (hs-CRP), creatinine, glucose, glycated hemoglobin, low-density lipoprotein cholesterol, and levels of urine microalbumin/creatinine ratio (UACR), sodium, and potassium were quantified.Results: A total of 118 women involving 40 with previous preeclampsia (PE), 27 with gestational hypertension (GHT), 10 with chronic hypertension (CHT) during recent pregnancy, and 41 normotensive pregnancies were enrolled at 6 weeks postpartum, of whom 73 (61.9%) completed the study at 6-12 months postpartum. Women in the PE and GHT groups had significantly elevated blood pressure, serum hs-CRP and hypertension at 6 weeks and 6-12 months postpartum. Both the PE and CHT groups had an increase in UACR at 6-12 months postpartum. Multivariate linear regression showed that a history of PE and GHT was independently and persistently associated with increased postpartum blood pressure.Conclusion: Women with HDP had increased blood pressure, risk of hypertension, and increased levels of biomarkers associated with cardiovascular risk at both 6 weeks and 6-12 months postpartum, including serum hs-CRP and UACR. Women with HDP should be counselled about cardiovascular risks as early as 6 weeks postpartum.
{"title":"Cardiovascular Biomarkers and Blood Pressure at 6 Weeks and 6-12 Months Postpartum in Women With or Without Hypertensive Disorders During Pregnancy: A Prospective Study","authors":"Jarawee Sukmanee, Penkae Rothmanee, Wilaiwan Sriwimol, Anne Cathrine, T. Liabsuetrakul","doi":"10.31584/jhsmr.20231019","DOIUrl":"https://doi.org/10.31584/jhsmr.20231019","url":null,"abstract":"Objective: To measure and compare cardiovascular biomarkers and blood pressure in women with hypertensive disorders of pregnancy (HDP) to those with normotensive pregnancies evaluated at 6 weeks and 6-12 months after delivery.Material and Methods: A prospective cohort study of postpartum women following HDP and normotensive pregnancies at 6 weeks and 6-12 months postpartum was conducted. Postpartum blood pressure and cardiovascular biomarkers including body mass index (BMI), levels of serum high-sensitivity C-reactive protein (hs-CRP), creatinine, glucose, glycated hemoglobin, low-density lipoprotein cholesterol, and levels of urine microalbumin/creatinine ratio (UACR), sodium, and potassium were quantified.Results: A total of 118 women involving 40 with previous preeclampsia (PE), 27 with gestational hypertension (GHT), 10 with chronic hypertension (CHT) during recent pregnancy, and 41 normotensive pregnancies were enrolled at 6 weeks postpartum, of whom 73 (61.9%) completed the study at 6-12 months postpartum. Women in the PE and GHT groups had significantly elevated blood pressure, serum hs-CRP and hypertension at 6 weeks and 6-12 months postpartum. Both the PE and CHT groups had an increase in UACR at 6-12 months postpartum. Multivariate linear regression showed that a history of PE and GHT was independently and persistently associated with increased postpartum blood pressure.Conclusion: Women with HDP had increased blood pressure, risk of hypertension, and increased levels of biomarkers associated with cardiovascular risk at both 6 weeks and 6-12 months postpartum, including serum hs-CRP and UACR. Women with HDP should be counselled about cardiovascular risks as early as 6 weeks postpartum.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139155798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：